Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded revision v3.5.0 to the record history and removed revision v3.4.3.SummaryDifference0.0%

- Check21 days agoChange DetectedThe version history now shows an addition of Revision: v3.4.3 and removal of Revision: v3.4.2.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedStudy Status updated to Completed on 2026-02-25 and Recruitment Status updated accordingly, replacing the previous Active, not recruiting status.SummaryDifference0.2%

- Check49 days agoChange DetectedAn administrative update adds Revision: v3.4.2 to the history and removes the earlier funding/operating-status notice, reflecting system maintenance rather than study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check56 days agoChange DetectedSite-wide notice about government funding lapse was added, and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check64 days agoChange DetectedUI tweaks include showing the glossary, explaining color-coded highlights, and updating the revision label to v3.4.0; a capitalization change from 'No FEAR Act data' to 'No FEAR Act Data' was made.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.